| Ipilimumab/Nivolumab Regimen studied in …STUDIED_INderived43 of 43show fewer |
|---|
| → studied in | NCT07815574Phase 3 · not yet recruiting iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma · 43 trials list this drug (22 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04090710Phase 2 · completed SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer · 43 trials list this drug (22 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740941Phase 2 · not yet recruiting NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma · 43 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07501117Phase 1 · recruiting Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma · 43 trials list this drug (22 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05933265Phase 1/Phase 2 · active not recruiting Study of LP-184 in Patients With Advanced Solid Tumors · 43 trials list this drug (22 active) | — | — | Solid Neoplasm,Glioblastoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07563738Phase 1/Phase 2 · recruiting A 2-part Phase 1/2 Open-label Trial on ODM-212 · 43 trials list this drug (22 active) | — | — | Malignant Mesothelioma,Malignant Pancreatic Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07075120Phase 1 · recruiting Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer · 43 trials list this drug (22 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665206Phase 1/Phase 2 · recruiting Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors · 43 trials list this drug (22 active) | — | — | Adult Solid Neoplasm,Malignant Mesothelioma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07436390NA · completed IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma · 43 trials list this drug (22 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06999980Phase 2 · recruiting Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) · 43 trials list this drug (22 active) | — | — | Cutaneous Melanoma,Mucosal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06487156active not recruiting A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 43 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04334759Phase 3 · completed DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma · 43 trials list this drug (22 active) | — | — | Malignant Mesothelioma,Pleural Mesothelial Neoplasm,Pleural Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07338981Phase 3 · not yet recruiting The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. · 43 trials list this drug (22 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04326257Phase 2 · completed Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy · 43 trials list this drug (22 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06794775Phase 3 · recruiting SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma · 43 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07233668NA · not yet recruiting Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC · 43 trials list this drug (22 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07091695completed Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab · 43 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07215962active not recruiting Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% · 43 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03075423Phase 2 · completed Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC · 43 trials list this drug (22 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03647163Phase 1/Phase 2 · active not recruiting Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors · 43 trials list this drug (22 active) | — | — | Solid Neoplasm,Neuroendocrine Carcinoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04283890Phase 1/Phase 2 · active not recruiting PHP and Immunotherapy in Metastasized UM · 43 trials list this drug (22 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03235245Phase 2 · active not recruiting Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib · 43 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07079644completed Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database · 43 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024862active not recruiting Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy · 43 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04730544Phase 2 · active not recruiting Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. · 43 trials list this drug (22 active) | — | — | MSI-H Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06926790Phase 2 · recruiting Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) · 43 trials list this drug (22 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02523313Phase 2 · completed Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED · 43 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03510871Phase 2 · completed Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) · 43 trials list this drug (22 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06163170completed A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma · 43 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05200988Phase 2 · active not recruiting Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC · 43 trials list this drug (22 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 43 trials list this drug (22 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03083691Phase 2 · completed BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer · 43 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04203901Phase 2 · terminated Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma · 43 trials list this drug (22 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03351361Phase 3 · completed Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients · 43 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05714371completed Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma · 43 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02917772Phase 2 · completed Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma · 43 trials list this drug (22 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03061539Phase 2 · active not recruiting Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature · 43 trials list this drug (22 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03219775Phase 2 · unknown Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma · 43 trials list this drug (22 active) | — | — | Malignant Neoplasm,Transitional Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03065179Phase 2 · completed SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients · 43 trials list this drug (22 active) | — | — | Kidney Neoplasm,Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02716272Phase 2 · completed Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients · 43 trials list this drug (22 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04131621Phase 2 · unknown Nivolumab/Ipilimumab in Second Line CUP-syndrome · 43 trials list this drug (22 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04250246Phase 2 · unknown A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 · 43 trials list this drug (22 active) | — | — | Melanoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02460068Phase 3 · unknown A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis · 43 trials list this drug (22 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |